JP2000515111A - サイトカインおよび造血因子の内因性産生増強因子とその利用方法 - Google Patents

サイトカインおよび造血因子の内因性産生増強因子とその利用方法

Info

Publication number
JP2000515111A
JP2000515111A JP09521965A JP52196597A JP2000515111A JP 2000515111 A JP2000515111 A JP 2000515111A JP 09521965 A JP09521965 A JP 09521965A JP 52196597 A JP52196597 A JP 52196597A JP 2000515111 A JP2000515111 A JP 2000515111A
Authority
JP
Japan
Prior art keywords
gssg
pharmaceutically acceptable
glutathione
salt
oxidized glutathione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP09521965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000515111A5 (enExample
Inventor
ボリソビチ バラツォフスキィ，マルク
アンドレエビチ コゼムヤキン，レオニド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU95120403/14A external-priority patent/RU2089179C1/ru
Application filed by Individual filed Critical Individual
Publication of JP2000515111A publication Critical patent/JP2000515111A/ja
Publication of JP2000515111A5 publication Critical patent/JP2000515111A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
JP09521965A 1995-12-14 1996-12-10 サイトカインおよび造血因子の内因性産生増強因子とその利用方法 Withdrawn JP2000515111A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU95120403/14A RU2089179C1 (ru) 1995-12-14 1995-12-14 Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
WO96/00226 1996-08-08
PCT/RU1996/000226 WO1997021443A1 (en) 1995-12-14 1996-08-08 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
WO95120403 1996-08-08
PCT/RU1996/000340 WO1997021444A1 (en) 1995-12-14 1996-12-10 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007238577A Division JP2008001722A (ja) 1995-12-14 2007-09-13 サイトカインおよび造血因子の内因性産生増強因子とその利用方法

Publications (2)

Publication Number Publication Date
JP2000515111A true JP2000515111A (ja) 2000-11-14
JP2000515111A5 JP2000515111A5 (enExample) 2004-11-04

Family

ID=26653679

Family Applications (2)

Application Number Title Priority Date Filing Date
JP09521965A Withdrawn JP2000515111A (ja) 1995-12-14 1996-12-10 サイトカインおよび造血因子の内因性産生増強因子とその利用方法
JP2007238577A Pending JP2008001722A (ja) 1995-12-14 2007-09-13 サイトカインおよび造血因子の内因性産生増強因子とその利用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007238577A Pending JP2008001722A (ja) 1995-12-14 2007-09-13 サイトカインおよび造血因子の内因性産生増強因子とその利用方法

Country Status (8)

Country Link
EP (1) EP0869809B1 (enExample)
JP (2) JP2000515111A (enExample)
AT (1) ATE214936T1 (enExample)
AU (1) AU1113097A (enExample)
CA (1) CA2239874A1 (enExample)
DE (1) DE69620233T2 (enExample)
ES (1) ES2174124T3 (enExample)
WO (1) WO1997021444A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515629A (ja) * 2003-01-23 2006-06-01 シャイア ラボラトリーズ，インコーポレイテッド 吸収促進剤
JP2015531341A (ja) * 2012-09-28 2015-11-02 協和発酵バイオ株式会社 グルタチオンを含有する免疫増強剤

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101576A1 (en) * 1997-03-21 2004-05-27 Eiichiro Yagi Immunopotentiators
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
US6399372B1 (en) 1998-03-30 2002-06-04 I.D.M. Immuno-Designed Monocyte derived cells with immunostimulating properties, their preparation and uses
JP2000169371A (ja) * 1998-10-02 2000-06-20 Sankyo Co Ltd ジチオラン誘導体を含有する医薬
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US20070142267A1 (en) 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2229892C2 (ru) * 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких
US7173013B2 (en) 2001-06-08 2007-02-06 Sciclone Pharmaceuticals, Inc. Treatment of tuberculosis using immunomodulator compounds
RU2482868C1 (ru) * 2011-12-30 2013-05-27 Общество С Ограниченной Ответственностью "Ива Фарм" Средство для лечения диабета, фармацевтическая композиция и способ лечения заболеваний
RU2545900C2 (ru) * 2013-05-07 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Способ диагностики апоптоза лимфоцитов
RU2540500C2 (ru) * 2013-05-07 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Способ прогнозирования ранней стадии апоптоза
RU2659161C1 (ru) 2017-11-17 2018-06-28 Общество С Ограниченной Ответственностью "Ива Фарм" Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид
CN114617899B (zh) * 2022-04-14 2023-10-20 苏州大学附属儿童医院 S-腺苷甲硫氨酸在制备治疗脓毒血症相关性脑病药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277619A (ja) * 1985-06-04 1986-12-08 Otsuka Pharmaceut Factory Inc 肝疾患治療剤
JP2921124B2 (ja) * 1990-12-28 1999-07-19 千寿製薬株式会社 酸化型グルタチオンアルキルエステル
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5618823A (en) * 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
GB9303854D0 (en) * 1993-02-25 1993-04-14 Holt John A G Method for enhancing t-cell count

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515629A (ja) * 2003-01-23 2006-06-01 シャイア ラボラトリーズ，インコーポレイテッド 吸収促進剤
JP2015531341A (ja) * 2012-09-28 2015-11-02 協和発酵バイオ株式会社 グルタチオンを含有する免疫増強剤

Also Published As

Publication number Publication date
DE69620233D1 (de) 2002-05-02
WO1997021444A1 (en) 1997-06-19
ES2174124T3 (es) 2002-11-01
DE69620233T2 (de) 2002-11-14
EP0869809B1 (en) 2002-03-27
EP0869809A1 (en) 1998-10-14
JP2008001722A (ja) 2008-01-10
AU1113097A (en) 1997-07-03
CA2239874A1 (en) 1997-06-19
ATE214936T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
JP7549640B2 (ja) ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法
RU2089179C1 (ru) Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
JP2000515111A (ja) サイトカインおよび造血因子の内因性産生増強因子とその利用方法
SK137996A3 (en) Cancer treatment and metastasis prevention
EP3154596A1 (en) Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
JP2005538093A (ja) 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
WO1997021444A9 (en) Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
JP5667886B2 (ja) 癌患者の生存時間を増大させるための組成物及び化合物の使用方法
RU2153351C2 (ru) Средство для регулирования эндогенной продукции цитокинов и гемопоэтических факторов (варианты) и способ его использования
JPH11507056A (ja) グルタチオンアナログの代謝的効果
US6251857B1 (en) Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
TWI834868B (zh) 難治性癌症之預防或治療用之醫藥組合物
Li et al. Treadmill training improves neural function recovery in rats with spinal cord injury via JAK2/STAT3 signaling pathway and attenuating apoptosis
JP3068644B2 (ja) 異化性腸管関連疾患および宿主防衛機構障害の治療用医薬組成物
AU662883B2 (en) Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases
Panicker et al. Oral glucosamine modulates the response of the liver and lymphocytes of the mesenteric lymph nodes in a papain-induced model of joint damage and repair
JP2012214451A (ja) 炎症性疾患用アミノ酸組成物
JP2002302447A (ja) 局所投与用癌治療剤
Parr et al. Allogeneic bone marrow transplantation: procedures and complications
Mattar et al. Local infusion of FGF-saporin reduces intimal hyperplasia
JP2022133455A (ja) 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物
US20180303916A1 (en) Compositions and methods for the treatment of diseases involving mucin
Cabral et al. Toxic epidermal necrolysis-Lyell's syndrome
Stratton et al. Response of human adenocarcinoma to chemotherapy: as sole agents and in combination with sodium ibuprofen
Melnikova et al. Disorders of Thermoregulation. Pathogenesis of Tumor growth: Manual for independent work for the students of the 3rd course of international faculty speciality “General medicine” English medium of instruction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20031203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20031203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070612

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070706

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070706

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070913

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080826

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081125